Hims & Hers Health Inc. (NYSE:HIMS) has been one of 2025’s hottest telehealth stocks, nearly doubling in value year to date, but a deepening clash with Novo Nordisk A/S (NYSE:NVO) over compounded weight-loss drugs, and shifting FDA rules, has turned momentum into headwinds, sending shares sliding 10% in the past three months.
The telehealth company’s stock has surged to almost double year to date. However, over the last three months, the stock has fallen around 10%. In June, the stock cratered almost 30% when Novo Nordisk discontinued working with the company in relation to direct access to Wegovy (semaglutide).
